<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02877355</url>
  </required_header>
  <id_info>
    <org_study_id>NN9924-4267</org_study_id>
    <secondary_id>2015-004534-10</secondary_id>
    <secondary_id>U1111-1175-5246</secondary_id>
    <nct_id>NCT02877355</nct_id>
  </id_info>
  <brief_title>Investigation of the Effect of Upper Gastrointestinal Disease on the Pharmacokinetics of Oral Semaglutide in Subjects With Type 2 Diabetes.</brief_title>
  <official_title>Investigation of the Effect of Upper Gastrointestinal Disease on the Pharmacokinetics of Oral Semaglutide in Subjects With Type 2 Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novo Nordisk A/S</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novo Nordisk A/S</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial is conducted in Europe. The aim of this trial is, to investigate the effect of
      upper gastrointestinal disease on the pharmacokinetics (the exposure of the trial drug in the
      body) of oral semaglutide in subjects with type 2 diabetes.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 22, 2016</start_date>
  <completion_date type="Actual">November 24, 2017</completion_date>
  <primary_completion_date type="Actual">November 24, 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area under the semaglutide plasma concentration-time curve</measure>
    <time_frame>From 0 to 24 hours after the 10th dosing</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum observed semaglutide plasma concentration</measure>
    <time_frame>From 0 to 24 hours after the 10th dosing</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the SNAC plasma concentration-time curve</measure>
    <time_frame>During a dosing interval (0 to 24 hours) at steady state</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum observed SNAC plasma concentration</measure>
    <time_frame>During a dosing interval (0 to 24 hours) at steady state</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">55</enrollment>
  <condition>Diabetes</condition>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>Semaglutide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>semaglutide</intervention_name>
    <description>All subjects will receive 3 mg oral semaglutide for five days followed by 7 mg oral semaglutide for five days</description>
    <arm_group_label>Semaglutide</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female, aged 18-80 years (both inclusive) at the time of signing informed
             consent

          -  Body mass index (BMI) between 18.5-39.9 kg/m^2 (both inclusive)

          -  Subjects diagnosed clinically with type 2 diabetes mellitus for at least 180 days
             prior to the first screening visit

          -  For subjects with upper gastrointestinal (GI) disease: Diagnosed with chronic
             gastritis and/or gastroesophageal reflux disease (GERD) at screening

        Exclusion Criteria:

          -  Female who is pregnant, breast-feeding or intends to become pregnant or is of
             child-bearing potential and not using a highly effective contraceptive method
             (adequate contraceptive measures as required by local regulation or practice). (Highly
             effective contraceptive methods are considered those with a failure rate less than 1%
             undesired pregnancies per year including surgical sterilisation, hormonal intrauterine
             devices (coil), oral hormonal contraceptives, sexual abstinence or a surgically
             sterilised partner)

          -  History of pancreatitis (acute or chronic)

          -  History of major surgical procedures involving the stomach potentially affecting
             absorption of trial product (e.g. subtotal and total gastrectomy, sleeve gastrectomy,
             gastric bypass surgery)

          -  Unable or unwilling to refrain from smoking during the in-patient periods

          -  Any blood draw in excess of 50 mL in the past 30 days, or donation of blood or plasma
             in excess of 400 mL within 90 days of the first screening visit
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Mainz</city>
        <zip>55116</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Neuss</city>
        <zip>41460</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://novonordisk-trials.com</url>
    <description>Clinical Trials at Novo Nordisk</description>
  </link>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 19, 2016</study_first_submitted>
  <study_first_submitted_qc>August 19, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 24, 2016</study_first_posted>
  <last_update_submitted>May 22, 2018</last_update_submitted>
  <last_update_submitted_qc>May 22, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 23, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
    <mesh_term>Gastrointestinal Diseases</mesh_term>
    <mesh_term>Digestive System Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>According to the Novo Nordisk disclosure commitment on novonordisk-trials.com</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

